Juan Carlos Alcedo

Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix

Alfonso Dueñas‐González, Juan José Zarbá, Firuza D. Patel et al. · Journal of Clinical Oncology · 2011 · 468 citations · Full text

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

David Miles, David Cameron, Igor Bondarenko et al. · European Journal of Cancer · 2016 · 121 citations

First-line Therapy, Breast Oncology, Prospective Biomarker Evaluation +8

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Eleftherios P. Mamounas, Michael Untch, Max S. Mano et al. · Annals of Oncology · 2021 · 119 citations · Full text

Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: Report of two successfully treated cases

Juan Carlos Alcedo, José Manuel Fábrega, Juan Ramón Arosemena et al. · Head & Neck · 2004 · 93 citations

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

Joyce O’Shaughnessy, Susana Sousa, Josefina Cruz et al. · European Journal of Cancer · 2021 · 67 citations · Full text